| Vol. 13.18 – 24 July, 2024 |
| |
|
|
| Scientists reported that Phf6 knockout increased the aggressiveness of Hoxa9-driven acute myeloid leukemia over serial transplantation, and increased the frequency of leukemia initiating cells. [Leukemia] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| TSP50 was negatively correlated with the prognosis of patients with breast cancer. TSP50 promoted CSC-like traits and EMT in both breast cancer cells and mouse xenograft tumor tissues. [Journal of Experimental & Clinical Cancer Research] |
|
|
|
| The authors combined the analysis of molecular data from T-ALL/LBL patients with the generation of hematopoietic cellular models to reveal that JAK/STAT pathway mutations are associated with an aberrant transcriptional profile. [NPJ Precision Oncology] |
|
|
|
| Researchers identified Nuclear Factor IX as a critical regulator of cancer stemness in gastric cancer and evaluated its clinicopathological significance and function. [Cancer Science] |
|
|
|
| The authors enriched ovarian cancer stem-like cells (OCSCs) through mammosphere culture, as an OCSC model. OCSLCs displayed heightened ferroptosis susceptibility, correlating with elevated FXN levels compared to non-stem ovarian cancer cells. [iScience] |
|
|
|
| Investigators generated HOXC transcript antisense RNA (HOTAIR) knock-out high-grade serous ovarian cancer cell lines using paired CRISPR guide RNA design to investigate the function of HOTAIR. [Molecular Cancer Therapeutics] |
|
|
|
| Researchers investigated the cellular characteristics of circulating tumor cells focusing on monitoring during atezolizumab and bevacizumab therapy in patients with HCC. Peripheral blood samples were collected from 10 healthy controls and 40 patients with HCC. [Heliyon] |
|
|
|
| Ovarian cancer cells were treated with Docetaxel (Doc), and then the effect of Doc on cellular viability was evaluated by MTT assay and microscopic imaging analysis. [PLOS One] |
|
|
|
|
| Scientists provide an update on the current development landscape of HER2-targeted therapies beyond breast cancer, as well as anticipated future HER2-directed treatment strategies to overcome resistance and thereby improve efficacy and patient outcomes. [Nature Reviews Clinical Oncology] |
|
|
|
| Investigators review advances in understanding multiple myeloma (MM) stem cells (MMSCs) and their role in drug resistance to MM therapies. They also discuss novel therapeutic strategies to overcome MM stem cell-mediated relapses and drug resistance. [Trends In Cancer] |
|
|
|
|
| Researchers have tried a bunch of strategies to get more negative results into the literature. Nature asks whether they are working. [Nature News] |
|
|
|
| Vickie Baracos, University of Alberta oncology professor, researcher and Alberta Cancer Foundation Chair in Palliative Medicine from 2003-23, was recently awarded the Order of Canada. She was honoured for her groundbreaking insights into the fundamental biology of cachexia. [University of Alberta] |
|
|
|
|
| August 26 – 30, 2024 Copenhagen, Denmark |
|
|
|
|
|
| Dalhousie University – Halifax, Nova Scotia, Canada |
|
|
|
| City of Hope – Monrovia, California, United States |
|
|
|
| Indiana University School of Medicine – Indianapolis, Indiana, United States |
|
|
|
| University of Cincinnati – Cincinnati, Ohio, United States |
|
|
|
| Amgen, Inc. – Houston, Texas, United States |
|
|
|
|